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Abstract Early experience in MS generated concerns that
interferon beta treatment might provoke onset or worsening
of depression. The objective of the study was to compare
depression incidence in relapsing–remitting MS patients
receiving interferon beta-1b (IFNB-1b) or glatiramer
acetate (GA) in the BEYOND trial. 891/897 (99 %) of
English, French, Spanish and Italian speakers among 2244
patients randomized (2:2:1) to receive either IFNB-1b
500 lg, 250 lg, or GA 20 mg QD for 2–3.5 years
submitted Beck Depression Inventory Second Edition
(BDI-II) scores at screening and serially thereafter, in
which scores C14 indicated depression. Baseline BDI-II
scores C14 were reported in 232/891 patients (26.3 %),
with no meaningful difference among the three treatment
arms noted at this or at any other time during the study
including trial end. Percentages of patients depressed by
BDI-II scores deviated little in any arm at any time (IFNB-
1b 500 lg: 24.7 %, IFNB-1b 250 lg: 24.4 %, GA:
32.4 %). Antidepressant usage was likewise similar among
the three treatment arms (IFNB-1b 500 lg: 33.7 %, IFNB-
1b 250 lg: 31.8 %, GA: 28.8 %) as was depression
severity and the frequency with which non-blinded treating
physicians recorded depression as an adverse event (IFNB-
1b 500 lg: 17.2 %, IFNB-1b 250 lg: 17.0 %, GA:
14.4 %). Treating physicians attributed depression to
IFNB-1b 250 lg therapy in 53.6 % and to GA in 21.9 % of
instances. This large, prospective, randomized-controlled
MS dataset showed no increased risk of depression above
baseline values with standard or double-dose IFNB-1b or
GA QD treatment.
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Introduction
Multiple sclerosis is an inflammatory, demyelinating disease
of the central nervous system that follows an unpre-
dictable course [1]. Multifocal involvement of CNS white
and gray matter can produce a multitude of clinical signs and
symptoms that can cause accumulating physical impairment
and disability. MS is frequently accompanied by cognitive
and psychological changes that often lessen patient quality of
life, occupational competence, and social interactions [2, 3].
Notably, depression is present at any given point in time in
approximately one-quarter of MS patients versus 5 % of the
population at large. Furthermore, the lifetime incidence of
significant depressive symptomatology in MS patients can
exceed 50 %, considerably higher than the 16 % estimated
lifetime incidence of major depressive disorder in the US
population at large [3–13]. Overall, it is now widely accepted
that the rate of suicide in MS is significantly increased as
compared to the underlying population [14].
Several interferon beta (IFNB) formulations are used to
treat relapsing–remitting MS (RRMS) [6, 15]. Early
experience with IFNB was interpreted by regulatory
authorities as suggesting agent-related development and
worsening of depressive symptoms. When depression
develops in IFNB-treated patients, a careful consideration
of treatment cessation has been advised [16–19]. In several
reports, an association between IFNB therapy and depres-
sion has been proposed: included are case studies of indi-
viduals suffering from depression after starting IFNB
treatment [20], depression recorded as adverse events
during clinical trials and depression, accepted as such,
based on response to non-validated questionnaires [21].
Yet, depression data collected during clinical trials in MS
using validated instruments has consistently failed to doc-
ument any such association [22].
Perceived links between IFNB and depression may be
colored in part by the frequency of underlying depression in
the absence of therapy; potential relationships between the
distress that often follows a recent diagnosis of MS; dread of
injections; the tendency for MS to worsen; and mood alter-
ations triggered by concomitantly administered medications
[23]. Depression is a well-established risk factor for suicide
by MS patients [2, 24], such that a clear understanding of any
association—or its absence—between IFNB therapies and
depression is desirable. To this end, we retrospectively
compared the incidence and severity of depression in 891
English-, French-, Spanish- or Italian-speaking patients
among the 2244 patients enrolled in the Betaseron Efficacy
Yielding Outcomes of a New Dose (BEYOND) trial.
Patients and methods
Patients with RRMS were randomized in the BEYOND
trial (NCT00099502) to receive either IFNB-1b 250 or
500 lg every other day or glatiramer acetate (GA) 20 mg
daily in a 2:2:1 ratio using block randomization with
regional stratification [25]. Patients were followed per
protocol for 2 years, with patients continuing on random-
ized therapy until the last entered patient had reached the
2-year study end. Patients randomized early during
recruitment were followed for a maximum of up to
3.5 years. Treating physicians and patients were aware of
allocation to IFNB or GA, but were blinded to IFNB dose.
Evaluating physicians were blinded to all treatment
assignments [25]. BEYOND was performed in accordance
with Good Clinical Practice and the International Confer-
ence on Harmonization (ICH) guidelines. The institutional
review boards of all participating centers approved the
study protocol. Patients provided written informed consent.
Study population
Treatment-naı¨ve patients with RRMS from 26 countries who
met the 2001 McDonald diagnostic criteria for MS [26] were
eligible for inclusion in BEYOND if aged between 18 and
55 years, had at least one relapse in the year before study
entry, and had a baseline Expanded Disability Status Scale
(EDSS) [27] score of B5. Patients were excluded from the
study if they presented with progressive forms of MS, or if
they had received either experimental or approved treatment
for MS. Importantly, patients with a history of severe
depression, a previous suicide attempt, or current suicidal
ideation were also excluded.
Assessment of depression
Depression and suicidal ideation were assessed on a
quarterly basis (every 12 weeks) using the Beck Depres-
sion Inventory Second Edition (BDI-II) [28] in English-,
French-, Spanish- and Italian-speaking patients, because
validated versions were only available in these languages.
The BDI-II is a self-administered rating inventory con-
sisting of 21 items that measures attitudes and symptoms
suggestive of depression, including feelings of hopeless-
ness and guilt, irritability and fatigue, as well as sleep
patterns and loss of appetite. Each item is rated on an
intensity scale of 0–3, with a maximum score of 63. Total
scores of B13 indicate no or insignificant depression, while
scores in the range of 14–19 suggest mild; 20–28, moder-
ate; and C29, severe depression [28].
Guided by the Goldman Consensus statement recom-
mendations on scoring depression in MS, BDI-II scores
were dichotomized: B13 taken as no or minimal depression
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and C14 as presence of depression—be it mild, moderate,
or severe [29].
Treating physicians, as part of their routine monitoring of
adverse events, recorded their subjective estimation of
depression occurrence at each office visit and provided an
opinion as to whether there was a relationship between treat-
ment given and depression in patients thought to be depressed.
Antidepressant usage
Information on antidepressant use by study participants was
collected at each office visit. The co-medication database
was searched using the following search terms: ‘‘antide-
pressants,’’ ‘‘nonselective monoamine reuptake inhibitors,’’
‘‘selective serotonin reuptake inhibitors,’’ ‘‘nonselective
monoamine oxidase inhibitors,’’ ‘‘monoamine oxidase A
inhibitors,’’ ‘‘other antidepressants,’’ ‘‘antidepressants in
combination with psycholeptics,’’ and ‘‘lithium.’’
Statistics
Descriptive statistics and Fisher’s exact test at the 0.05
level of significance (post hoc) were used for data analyses.
Results
Study population
Altogether, 2244 patients were randomized in the multi-
national BEYOND study. The majority were female (1562/
2244; 69.6 %) and Caucasian (2045/2242; 91.2 %). Most
patients (1786/2244; 79.6 %) had an EDSS score at
screening of 1.0–3.5. The mean age at disease onset was
31.0 ± 9.1 years and mean disease duration was
5.3 ± 5.8 years (Table 1). A total of 24 patients did not
receive treatment with study medication and accordingly
were omitted from the per-protocol analysis. Baseline
demographics and disease characteristics were similar
across the treatment groups, as described in more detail
elsewhere [25].
Depression assessed by BDI-II
The BDI-II enabled assessment of patients from Australia,
Canada, the USA, France, Italy, and Spain. Validated
language versions were not available for 60.0 % (1347/
2244) of randomized patients. A total of 39.7 % of ran-
domized patients (891/2244) had BDI-II scores recorded at
screening (proportion in each treatment arm: IFNB-1b
500 lg, 40.2 % [361/899]; IFNB-1b 250 lg, 39.8 % [357/
897]; GA, 38.6 % [173/448]). Only six patients eligible for
BDI-II testing did not perform a screening assessment. Of
patients with screening BDI-II scores, 74.0 % overall (659/
891) had BDI-II scores B13, indicating no or minimal
depression, while 26.0 % (232/891) had scores C14, sug-
gesting mild to severe depression (proportion in each
treatment arm: IFNB-1b 500 lg, 24.7 % [89/361]; IFNB-
1b 250 lg, 24.4 % [87/357]; GA, 32.4 % [56/173]). No
significant differences in depression severity were found
between treatment arms at screening (IFNB-1b 500 lg vs.
GA, p = 0.062; IFNB-1b 250 lg vs. GA, p = 0.060).
Patients with BDI-II scores C14 had higher baseline
EDSS scores (p\ 0.0001) and more relapses in the 2 years
prior to enrollment (p = 0.0017) than patients with scores
B13 (Table 2). However, patients with higher baseline
depression scores had fewer gadolinium-enhancing lesions
and lower gadolinium-enhancing lesion volume at baseline
Table 1 Baseline
characteristics of participants
randomized in the BEYOND
study
IFNB-1b 500 lg IFNB-1b 250 lg GA Total
n = 899 n = 897 n = 448 N = 2244
Duration of disease
N 899 896 448 2243
Mean (range, SD), years 5.4 (0–33, 5.8) 5.3 (0–42, 5.8) 5.1 (0–29, 5.6) 5.3 (0–42, 5.8)
Age at onset
N 899 896 448 2243
Mean (range, SD), y 31.1 (9–55, 9.2) 31.1 (10–53, 9.2) 30.6 (8–55, 9.0) 31.0 (8–55, 9.1)
Number of relapses during the previous year
N 899 896 448 2243
Mean (range, SD), 1.6 (0–8, 0.8) 1.6 (1–5, 0.7) 1.6 (0–5, 0.8) 1.6 (0–8, 0.7)
Total number of previous relapses
N 894 888 448 2230
Mean (range, SD) 3.5 (1–30, 2.6) 3.5 (1–30, 2.7) 3.7 (1–21, 2.6) 3.5 (1–30, 2.6)
BEYOND Betaseron Efficacy Yielding Outcomes of a New Dose [trial], GA glatiramer acetate, IFNB-1b
interferon beta-1b
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Table 2 Baseline
characteristics of patients by
BDI-II scores at screening
Screening BDI-II score B 13 Screening BDI-II score C 14
n = 659 n = 232
Female
n/N 479/659 (72.7 %) 181/232 (78.0 %)
p value 0.1175
Caucasian
n/N 577/658 (87.7 %) 195/231 (84.4 %)
p value 0.2141
Age
N 659 232
Mean (range, SD), years 38.0 (18–57, 9.1) 38.0 (18–55, 9.0)
p value 0.8577
Duration of disease
N 659 232
Mean (range, SD), years 4.7 (0–42, 5.8) 4.9 (0–32, 5.7)
p value 0.4159
Relapse rate in the previous 2 years
N 657 232
Mean (range, SD) 1.9 (1.0–10.0, 1.0) 2.2 (1.0–15.0, 1.3)
p value 0.0017
Two or more relapses in the previous 2 years
n/N 433/657 (65.9 %) 173/232 (74.6 %)
p value 0.0173
EDSS
N 651 227
Mean (range, SD) 2.0 (0–5.5, 1.1) 2.7 (0–6.0, 1.2)
p value \0.0001
T2 lesion volume (cm3)
N 657 230
Mean (range, SD) 7.0 (0.1–72.7, 8.4) 6.6 (0.1–102.0, 9.6)
p value 0.2312
T1-hypointense lesion volume (cm3)
N 648 227
Mean (range, SD) 1.2 (0–26.1, 2.5) 1.1 (0–39.1, 2.9)
p value 0.3305
One or more Gd-enhancing lesions
n/N 295/659 (44.8 %) 82/232 (35.3 %)
p value 0.0134
Gd-enhancing lesion volume (cm3)
N 651 229
Mean (range, SD) 0.22 (0–6.7, 0.6) 0.16 (0–5.8, 0.5)
p value 0.0163
Normalized brain volume (cm3)
N 648 228
Mean (range, SD) 1502.9 (1171–1804, 106.7) 1494.7 (1142–1764, 103.2)
p value 0.3121
BDI-II Beck Depression Inventory Second Edition, EDSS Expanded Disability Status Scale, GD
gadolinium
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(p = 0.0134 and p = 0.0163, respectively) than partici-
pants with screening BDI-II scores B 13.
The number and relative proportion of patients in each
treatment group with BDI-II scores B13 or C14 at each
time point stratified by BDI-II score at screening are pre-
sented in Fig. 1 and Supplemental Fig. 1. At all time
points, the proportion of patients with depression was
marginally smaller for both IFNB-1b doses than for GA,
but the differences were not significant (IFNB-1b 500 lg
vs. GA, p = 0.882; IFNB-1b 250 lg vs. GA, p = 0.879).
At study end, BDI-II scores were provided by 794
patients, 567 of whom (71.4 %) were not depressed (BDI-
II score B13). Of 598 patients not depressed at baseline
(scores B13), 108 (18.1 %) became depressed at some time
during the trial (scores rose to C14). The upward shift was
similar among the three treatment arms (IFNB-1b 500 lg,
47/248 [18.9 %]; IFNB-1b 250 lg, 42/244 [17.2 %]; GA,
19/106 [17.9 %]; IFNB-1b 500 lg vs. GA, p = 0.88;
IFNB-1b 250 lg vs. GA, p = 0.88; Fig. 2a).
In contrast, among the 196 patients who were depressed
at baseline (BDI-II score C14), depression lifted (BDI-II
score fell to B13) during the trial in 77 (39.3 %), with once
again an indistinguishable downward shift among treat-
ment arms (IFN-1b 500 lg, 32/73 [43.8 %]; IFN-1b
250 lg, 25/75 [33.3 %]; GA, 20/48 [41.7 %]; IFN-1b
500 lg vs. GA, p = 0.85; IFN-1b 250 lg vs. GA,
p = 0.44; Fig. 2b).
Depression as a clinically determined adverse event
The frequency with which depression was reported as an
adverse event by non-blinded treating physicians was
similar for IFNB-1b 500 lg (153/887, 17.2 %); IFNB-1b
250 lg (151/888 17.0 %); and GA (64/445 14.4 %)—
IFNB-1b 500 lg vs. GA (p = 0.40); IFNB-1b 250 lg vs.
GA (p = 0.24) (Fig. 3).
Treating physicians viewed depression severity as mild
to moderate in most cases (IFNB-1b 500 lg, 137/153
[89.5 %]; IFNB-1b 250 lg, 137/151 [90.7 %]; GA, 61/64
[95.3 %]). Depression as the basis for premature medica-
tion discontinuation was recorded in \1 % of patients
(IFNB-1b 500 lg, 8/887 [0.9 %]; IFNB-1b 250 lg, 8/888
[0.9 %]; GA, 0/445 [0 %]).
Depression ascribed to treatment
Although reporting of depression as an adverse event was
similar across the three treatment arms, treating physicians
viewed depression as therapy related more than twice as
often for patients treated with IFNB-1b as for those treated
with GA (IFNB-1b 500 lg, 85/153 [55.6 %]; IFNB-1b
250 lg, 81/151 [53.6 %]; GA, 14/64 [21.9 %]). Of note,
treating physicians knew which patients had been
randomized to IFNB-1b (although dose was not known) or
to GA.
Incidence of suicidal ideation and suicide
The incidence of suicidal ideation in the BEYOND study
was low in all three treatment groups (IFNB-1b 500 lg,
2/887 [0.2 %]; IFNB-1b 250 lg, 3/888 [0.3 %]; GA, 1/445
[0.2 %]). Nevertheless, suicidal ideation—though rare—
was attributed by the treating physician to IFNB-1b treat-
ment in 5/5 cases, but not to GA in the single recorded
instance of suicidal ideation in this treatment arm.
Two patients, both randomized to IFNB-1b 250 lg (2/
888, 0.2 %), attempted suicide at 0.7 and 2.8 years into the
study. One attempt was thought to possibly be
attributable to treatment. Two additional patients, one
randomized to IFNB-1b 500 lg (1/887, 0.1 %) and one to
GA (1/445, 0.2 %), completed suicide at 1.8 and 0.6 years
into the study, respectively. Neither instance was deemed
to be related to treatment.
Antidepressant usage
The proportions of patients treated with antidepressant
medication at some point during the BEYOND study were
similar across the treatment arms: IFNB-1b 500 lg, 33.7 %
(299/887); IFNB-1b 250 lg, 31.8 % (282/888); GA,
28.8 % (128/445) (IFNB-1b 500 lg vs. GA, p = 0.07;
IFNB-1b 250 lg vs. GA, p = 0.28).
Discussion
The incidence and severity of depression in RRMS patients
treated with either of two doses of IFNB-1b or with GA in
the multinational BEYOND clinical trial were evaluated
prospectively using a validated instrument for assessing
depression. The exclusion of patients with a clinical history
of severe depression, attempted suicide or suicidal ideation
reduced the potential confounders for this analysis.
Twenty-six percent of entrants had a BDI-II score C14 at
screening, indicative of depression of at least mild severity.
Patients with BDI-II scores C14 at screening had higher
relapse rates in the 2 years preceding entry and higher
EDSS scores at baseline than patients with BDI-II scores
\13. Intriguingly, they also had fewer gadolinium-en-
hancing lesions, suggesting that clinically apparent relapses
might be a more reliable indicator of depression than
gadolinium positivity.
At trial entry, numerically fewer patients randomly
assigned to IFNB-1b (either dose) had BDI-II total scores
indicative of clinical depression than patients assigned to
GA. These differences, while minor, persisted over the
1422 J Neurol (2016) 263:1418–1426
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course of the trial, although they never reached significance
at any time point. More importantly, similar proportions of
patients in all three arms without depression at study entry
progressed to BDI-II scores indicative of depression during
the trial, while comparative numbers of patients in all three
arms with BDI-II score suggestive of depression at study
entry reverted to non-depressed status during the trial.
These two trends largely offset one another, such that the
incidence of depression remained relatively constant
among all three arms throughout the course of the trial.
Antidepressant usage was likewise comparable across all
three treatment arms.
Despite the above, treating physicians were far more
likely to cite depression as a complication of IFNB-1b
treatment than as a complication of GA treatment. Labels
for IFNB warn of depression and suicide, whereas labels
for GA carry no such warning; this difference may have
accounted for an attribution bias. Although the non-
blinding of physicians could be considered a limitation of
the study, the frequency with which non-blinded treating
physicians clinically stated depression as an adverse event
was substantially lower than the frequency with which
depression was suggested by the BDI-II across all three
treatment groups. Thus, the data presented here suggest
that awareness of the patient’s treatment did not substan-
tially influence reporting of clinical depression and
underscore the value of screening with a validated instru-
ment to get a full sense of depression frequency in MS.
Another possible limitation of the present study is the
absence of a placebo-treated control group. Consequently,
the issue of whether IFNB-1b and GA therapies are both
associated with depression, or neither therapy is so asso-
ciated, cannot be resolved definitively by the available data
presented here. In addition, only a relatively small per-
centage of patients (approximately, 40 %) completed the
BDI. However, it is important to note that the percentage of
patients with BDI data in each treatment group was similar.
Nonetheless, the present study provides strong support to a
considerable body of literature favoring the view that nei-
ther agent is linked to aggravating or inducing clinical
depression. First, GA has not been perceived to be asso-
ciated with depression in placebo-controlled or open-label
studies nor as a spontaneously reported adverse event.
Second, outcomes from the BEYOND study match data
generated in other randomized, placebo-controlled trials of
IFNB: no significant difference in the occurrence of
patient-reported depression was found between IFNB-1b
and placebo in the original IFNB-1b trial [30]. Similarly, in
the 2-year study comparing intramuscular IFNB-1a with
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placebo, BDI-II scores did not differ at any time point
between treatment groups [6]. In the ‘‘Prevention of
Relapses and Disability by IFNB-1a Subcutaneously in
Multiple Sclerosis’’ (PRISMS) study, no relationship
between IFNB-1a treatment and clinically significant
depression was found over 24 months (relative risk,
0.3–1.8) compared with placebo [31]. Furthermore, in a
pooled analysis of 6 controlled studies and 17 non-con-
trolled trials, subcutaneous IFNB-1a therapy was not linked
to an increase in depression severity or suicide risk [22]
and a controlled, epidemiologic study that assessed
depression in 50 Italian RRMS patients and 50 healthy
controls using a variety of methods (Structured Clinical
Interview for Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV), BDI, and State Trait Anxiety
Inventory) concluded that IFNB therapy was not a risk
factor for depression [32]. A sizable head-to-head
(n = 764) clinical trial comparing subcutaneous IFNB-1a
versus GA found no significant differences in the propor-
tions of patients reporting depression as an adverse event
[33]. Last, IFNB-1b- and GA-treated patients identified in a
health-care database exhibited no differences in antide-
pressant usage, a useful proxy for depression incidence
[34]. Collectively, these data—reinforced by the results
presented here—provide compelling evidence to support
the hypothesis that IFNB neither causes nor exacerbates
depression in patients with MS.
We recognize that MS patients with a history of
depression may be more vulnerable to subsequent depres-
sion than those without such a history, and that disease
activity may herald future depression. In the BEYOND
study, patients with active depression or a clinical history
of severe depression were excluded, and the majority of
participants exhibited low disease activity over the 3-year
study duration. While the absence of patients with a pre-
vious history of depression in the BEYOND study popu-
lation may limit the generalizability of our findings, no
biological signal was detected in this patient cohort and
IFNB-1b was not found to induce or exacerbate depressive
symptoms.
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